{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-045445","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2025-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.059475+00:00","generated_at":"2026-05-17T03:14:47.087531+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arvinas reports positive PRO data from Phase 3 VERITAC-2 for vepdegestrant in ESR1-mutated breast cancer","bullets":["Vepdegestrant showed reduced risk of deterioration vs fulvestrant in overall health status, pain severity, and functioning domains; statistically significant.","PRO data presented at ESMO 2025 support vepdegestrant as potential best-in-class therapy for ESR1-mutated ER+/HER2- metastatic breast cancer.","Also presented TACTIVE-N Phase 2 results: neoadjuvant vepdegestrant demonstrated biological and clinical activity in localized breast cancer.","Vepdegestrant is a PROTAC ER degrader developed with Pfizer; previously reported statistically significant PFS improvement."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-045445","json":"https://secwatch.observer/filing/0001628280-25-045445.json","markdown":"https://secwatch.observer/filing/0001628280-25-045445.md","text":"https://secwatch.observer/filing/0001628280-25-045445.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000162828025045445/0001628280-25-045445-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000162828025045445/arvn-20251020.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:14:47.087531+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}